Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Florian ScottéKristi McIntyreSharon WilksShannon PuhallaJoyce O'ShaughnessyErhan BerrakYaohua HeLinda VahdatPublished in: BMC cancer (2019)
NCT01268150 (December 29, 2010), NCT01269346 (January 4, 2011).